Exact Sciences Corporation (EXAS)
$104.91+0.00%Close
BUYBULL · day 78
Key stats
- Market cap
- $20.0B
- Beta
- 1.44
- P/E (TTM)
- -188.59
- 1W
- +1.02%
- 1M
- +1.43%
- vs SPY 1W
- +0.60%
- vs SPY 1M
- -0.63%
Industry peers
FMP comparable companies · ranked by market cap
- RVMDSELLRevolution Medicines, Inc.$41.2BRECOVERYQ 30$193.95+2.21%
- ROIVSELLRoivant Sciences Ltd.$25.0BBEARQ 30$34.59-2.40%
- GHSELLGuardant Health, Inc.$21.8BCRISISQ 23$162.79-2.79%
- VTRSBUYViatris Inc.$20.4BBULLQ 5$17.54-0.57%
- RVTYBUYRevvity, Inc.$17.4BBULLQ 12$155.61+0.93%
- SMMTBUYSummit Therapeutics Inc.$13.7BRECOVERYQ 17$17.13-2.62%
- BBIOSELLBridgeBio Pharma, Inc.$12.9BRECOVERYQ 18$65.75+0.61%
- ICLRSELLICON Public Limited Company$12.6BRECOVERYQ 17$164.40+0.14%
- QGENBUYQiagen N.V.$9.3BRECOVERYQ 16$45.31-0.15%
- DOCSBUYDoximity, Inc.$5.7BRECOVERYQ 8$30.58+0.26%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on EXAS?
- LOPJLB’s latest quantitative signal on Exact Sciences Corporation (EXAS) is BUY in a BULL regime. Signals are updated daily.
- What market regime is EXAS in?
- Exact Sciences Corporation (EXAS) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Exact Sciences Corporation (EXAS) do?
- Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio a…